Intravacc has developed several platforms to reduce time and costs for the development of new vaccines.
These are the Cell-based platform, the OMV platform and conjugation platform. In 2020 Intravacc in-licensed the iBoost platform.
These platforms are built on the extensive knowledge that Intravacc has obtained in the long history of the company. This knowledge is captured in general procedures that form the blueprints to quickly design and develop
The goal is to use the already developed techniques and assays ‘as is’ for new vaccines with some small optimization studies.